Upregulated Cellular Expression of IL-17 by CD4+ T-Cells in Osteoporotic Postmenopausal Women

Annals of Nutrition and Metabolism

Volumn 68, Issue 2, 2016, Pages 113-118

  Zhao, Renqing ^a   Wang, Xinzheng ^a   Feng, Feifei ^a  

^a ZHEJIANG NORMAL UNIVERSITY   (China)

Author keywords

IL 17; Menopause; Osteoporosis; T cells; Women

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 6; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; RORC PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; CD4+ T LYMPHOCYTE; CELLULAR EXPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESTROGEN DEFICIENCY; FAT MASS; FEMALE; FEMUR NECK; GENE EXPRESSION; HUMAN; LUMBAR SPINE; MENOPAUSE; OSTEOCLASTOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UPREGULATION; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; METABOLISM; MIDDLE AGED; POSTMENOPAUSE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-17; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; POSTMENOPAUSE; RANK LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84954424869     PISSN: 02506807     EISSN: 14219697     Source Type: Journal    
DOI: 10.1159/000443531     Document Type: Article

References (29)

1. Zaidi M: Skeletal remodeling in health and disease. Nat Med 2007; 13: 791-801.
2. Weitzmann MN, Pacifici R: Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006; 116: 1186-1194.
3. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M: Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008; 27: 535-545.
4. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S: Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007; 130: 811-823.
5. Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC: Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest 1998; 101: 1942-1950.
6. Pacifici R: Role of T cells in ovariectomy induced bone loss-revisited. J Bone Miner Res 2012; 27: 231-239.
7. Zhao R: Immune regulation of osteoclast function in postmenopausal osteoporosis: A critical interdisciplinary perspective. Int J Med Sci 2012; 9: 825-832.
8. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, Pacifici R: Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A 2001; 98: 13960-13965.
9. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R: Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000; 106: 1229-1237.
10. Devlin RD, Reddy SV, Savino R, Ciliberto G, Roodman GD: IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. J Bone Miner Res 1998; 13: 393-399.
11. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD: IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990; 144: 4226-4230.
12. Bellido T, Stahl N, Farruggella TJ, Borba V, Yancopoulos GD, Manolagas SC: Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J Clin Invest 1996; 97: 431-437.
13. D'Amelio P, Grimaldi A, Di Bella S, Brianza SZ, Cristofaro MA, Tamone C, Giribaldi G, Ulliers D, Pescarmona GP, Isaia G: Estrogen deficiency increases osteoclastogenesis upregulating T cells activity: A key mechanism in osteoporosis. Bone 2008; 43: 92-100.
14. D'Amelio P, Grimaldi A, Pescarmona GP, Tamone C, Roato I, Isaia G: Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB J 2005; 19: 410-412.
15. Koenders MI, Lubberts E, van de Loo FA, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Kolls JK, Di Padova FE, Joosten LA, van den Berg WB: Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol 2006; 176: 6262-6269.
16. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB: IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003; 170: 2655-2662.
17. DeSelm CJ, Takahata Y, Warren J, Chappel JC, Khan T, Li X, Liu C, Choi Y, Kim YF, Zou W, Teitelbaum SL: IL-17 mediates estrogendeficient osteoporosis in an Act1-dependent manner. J Cell Biochem 2012; 113: 2895-2902.
18. Tyagi AM, Srivastava K, Mansoori MN, Trivedi R, Chattopadhyay N, Singh D: Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: A new candidate in the pathogenesis of osteoporosis. PLoS One 2012; 7:e44552.
19. Molnár I, Bohaty I, Somogyiné-Vári É: IL-17A-mediated sRANK ligand elevation involved in postmenopausal osteoporosis. Osteoporos Int 2014; 25: 783-786.
20. McKane WR, Khosla S, Peterson JM, Egan K, Riggs BL: Circulating levels of cytokines that modulate bone resorption: effects of age and menopause in women. J Bone Miner Res 1994; 9: 1313-1318.
21. Ding QL, Tang GS, He ZW, Shen Q, Qin YH: The proportion of Th17 cells and IL-17 expression levels in peripheral blood of patients with chronic hepatitis B and their clinical significance. Lab Med 2014; 29: 15-20.
22. Zheng SX, Vrindts Y, Lopez M, De Groote D, Zangerle PF, Collette J, Franchimont N, Geenen V, Albert A, Reginster JY: Increase in cytokine production (IL-1 beta, IL-6, TNFalpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas 1997; 26: 63-71.
23. McNamara LM: Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface 2010; 7: 353-372.
24. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL: TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-1488.
25. Molnár I, Bohaty I, Somogyiné-Vári É: High prevalence of increased interleukin-17A serum levels in postmenopausal estrogen deficiency. Menopause 2014; 21: 749-752.
26. Zhang J, Fu Q, Ren Z, Wang Y, Wang C, Shen T, Wang G, Wu L: Changes of serum cytokines-related Th1/Th2/Th17 concentration in patients with postmenopausal osteoporosis. Gynecol Endocrinol 2015; 31: 183-190.
27. Won HY, Lee JA, Park ZS, Song JS, Kim HY, Jang SM, Yoo SE, Rhee Y, Hwang ES, Bae MA: Prominent bone loss mediated by RANKL and IL-17 produced by CD4+ T cells in TallyHo/JngJ mice. PLoS One 2011; 6:e18168.
28. Zhao R: Immune regulation of bone loss by Th17 cells in oestrogen-deficient osteoporosis. Eur J Clin Invest 2013; 43: 1195-1202.
29. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y: Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14: 518-527.